Huasun(SZ:000790) Zheng Quan Zhi Xing·2025-08-01 16:35Group 1 - The company Chengdu Huasheng Technology Group Co., Ltd. acquired 51% equity of Tibet Kangyu Pharmaceutical Co., Ltd. for RMB 51 million, making it a subsidiary included in the consolidated financial statements [1][2] - The transferor committed to achieving net profits of no less than RMB 15 million, RMB 20 million, and RMB 25 million for the years 2023 (August-December), 2024, and 2025 respectively [2][3] - If the net profit falls below 60% of the promised amount, the transferor must compensate the company in cash based on a specific formula [2][3] Group 2 - In 2024, Tibet Kangyu's net profit was RMB 16.7843 million, which is below the promised RMB 20 million, resulting in a cash compensation of RMB 6.5601 million from the transferor [4] - The performance compensation for the 2024 fiscal year has been fully executed [4]